Figure 3.
MDF VVPs exhibit enhanced in vivo functionality in a humanized NSG MHC I/II KO Nalm6 mouse model. (A) Human T-cell activation, as measured by CD25 and CD71, in humanized NSG MHC I/II KO model 4 days after VivoVec administration. (B) Percent CD19 CAR+ of human CD3+ cells and total human CD19 CAR+ cells per microliter blood (left) and representative flow plots (right) on day 11 after VivoVec administration. (C) Tumor burden over time as measured by Nalm6 bioluminescence. (D) Overall survival. For all figures, n = 7 to 8 for VivoVec groups and n = 3 for vehicle control. Two-tailed unpaired student t test for panels A-B. Two-way ANOVA with multiple comparisons for panel C. Log-rank Mantel Cox test for panel D. ∗∗∗∗P < .0001; ∗∗∗P < .0002; ∗∗P < .002; and ∗P < .03.

MDF VVPs exhibit enhanced in vivo functionality in a humanized NSG MHC I/II KO Nalm6 mouse model. (A) Human T-cell activation, as measured by CD25 and CD71, in humanized NSG MHC I/II KO model 4 days after VivoVec administration. (B) Percent CD19 CAR+ of human CD3+ cells and total human CD19 CAR+ cells per microliter blood (left) and representative flow plots (right) on day 11 after VivoVec administration. (C) Tumor burden over time as measured by Nalm6 bioluminescence. (D) Overall survival. For all figures, n = 7 to 8 for VivoVec groups and n = 3 for vehicle control. Two-tailed unpaired student t test for panels A-B. Two-way ANOVA with multiple comparisons for panel C. Log-rank Mantel Cox test for panel D. ∗∗∗∗P < .0001; ∗∗∗P < .0002; ∗∗P < .002; and ∗P < .03.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal